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HIV, Antiretroviral Therapy, 
and Cardiovascular Disease
Cardiovascular disease is an increasing 
cause of morbidity in HIV-infected 
adults receiving antiretroviral 
therapy (ART). ART, particularly 
protease inhibitors and to a lesser 
extent nucleoside analogue reverse 
transcriptase inhibitors, can adversely 
affect lipid and glucose metabolism [1]. 
Moreover, there is a strong correlation 
between ART duration and the risk of 
myocardial infarction, an association in 
part linked to higher plasma levels of 
total cholesterol and triglyceride and to 
lower levels of high-density lipoprotein 
(HDL) cholesterol [2]. Paradoxically, 
interruption of ART also appears to be 
associated with an increased short-term 
risk of cardiovascular disease [3]. These 
ﬁ  ndings suggest that HIV itself may 
also increase cardiovascular risk, and 
that control of HIV replication might 
reduce this risk.
HDL cholesterol levels are reduced 
in untreated HIV infection [4] and 
in healthy volunteers exposed for 
a short term to the HIV protease 
inhibitors ritonavir-boosted atazanavir 
and lopinavir [5,6]. In HIV-infected 
individuals who start ART that 
effectively suppresses HIV replication, 
HDL cholesterol levels increase, 
regardless of whether a protease 
inhibitor is used [7–9], implying that 
the HIV effect on HDL cholesterol 
levels is greater than the ART effect.
How Does HIV Lower HDL 
Cholesterol Levels?
The pathogenesis of low HDL 
cholesterol levels in untreated HIV 
infection is unknown. In a study 
recently published in PLoS Biology, 
Mujawar et al. investigated whether 
these lower levels might be due to 
impaired cholesterol efﬂ  ux from 
macrophages [10], a process mediated 
by the ABCA1 cell-surface cholesterol 
transporter. ABCA1 lipidates apoA-I, 
the major apolipoprotein in HDL, and 
thus plays a central role in formation 
of nascent HDL. Mutations in ABCA1 
cause Tangier disease, which is 
associated with low HDL cholesterol 
and accelerated atherosclerosis [11].
The researchers found that 
expression of HIV nef, a protein 
that enhances HIV replication and 
infectivity, speciﬁ  cally inhibited 
ABCA1-dependent cholesterol efﬂ  ux 
from macrophages (the precursors of 
foam cells in atherosclerotic plaque) 
and re-localized ABCA1 to an exclusive 
plasma membrane distribution. While 
nef-transfected cells exhibited increased 
apoA-I binding, apoA-I internalization 
was blocked, suggesting that nef at the 
plasma membrane may prevent ABCA1 
internalization and subsequent apoA-I 
lipidation. As cholesterol is required 
for HIV replication [12], Mujawar et 
al. next examined whether enhancing 
cholesterol efﬂ  ux from HIV-infected 
macrophages affected HIV replication. 
Using a liver X receptor (LXR) agonist 
to transcriptionally upregulate ABCA1, 
cholesterol efﬂ  ux was augmented, 
signiﬁ  cantly reducing virion-associated 
cholesterol and infectivity.
What Do the Findings Mean?
Mujawar et al. propose that HIV nef 
redirects cholesterol from an ABCA1-
mediated efﬂ  ux pathway to virus-
controlled cholesterol transport in 
order to ensure sufﬁ  cient cholesterol 
for virion assembly. The interruption 
of a host cholesterol trafﬁ  cking 
pathway by an intracellular pathogen 
is also employed by Toxoplasma gondii, 
in which endocytosed low-density 
lipoprotein cholesterol is diverted 
to a specialized vacuole to support 
parasite growth and replication [13]. 
Given that impaired ABCA1 function 
results in decreased HDL cholesterol 
and accelerated atherosclerosis [14], 
the ﬁ  ndings of Mujawar et al. provide 
a possible mechanism to explain low 
HDL cholesterol in HIV infection and 
increased cardiovascular risk in HIV-
infected adults.
It remains to be determined, 
however, if this mechanism is the 
greatest contributor to these low 
levels. If so, one would expect that 
HDL cholesterol levels would fall 
rapidly after primary HIV infection 
and return to pre-infection levels 
with effective ART that did not 
affect lipid metabolism. In addition, 
the observed reductions might be 
inversely proportionate to plasma HIV 
RNA levels. Alternatively, low HDL 
cholesterol levels may also be caused 
by ART-induced lipodystrophy. This 
ART side effect is characterized by 
peripheral lipoatrophy and relative 
central adiposity and is strongly 
associated with low HDL cholesterol 
levels as well as insulin resistance and 
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hypertriglyceridemia, all features of 
congenital lipodystrophies in which 
abnormalities of ABCA1 have not been 
identiﬁ  ed [2,15,16].
The Strengths and Limitations 
of the Study 
The ﬁ  ndings of Mujawar et al. raise 
several important questions. Is the 
apparent nef-stimulated decrease in 
ABCA1 protein levels due to ABCA1 
degradation, or possibly due to 
altered partitioning of ABCA1 into 
detergent-resistant lipid domains? Does 
nef physically interact with ABCA1? 
Use of the myristoylation-deﬁ  cient 
nef in this study only suggests that 
nef must be targeted to the plasma 
membrane—likely to cholesterol 
rafts [17]. Furthermore, experiments 
involving immunoprecipitation of raft-
associated proteins must be interpreted 
with caution, and should be followed 
up with more rigorous studies (e.g., 
identiﬁ  cation of interaction domains 
and ﬂ  uorescence resonance energy 
transfer) that provide support for a 
speciﬁ  c ABCA1–nef interaction at the 
plasma membrane. Finally, might LXR 
ligands activate target genes, other than 
ABCA1, that could attenuate virion-
associated cholesterol? Treatment 
of HIV-infected ABCA1-deﬁ  cient 
macrophages with LXR ligands should 
establish a deﬁ  nitive role for ABCA1 in 
countering HIV replication.
Where To From Here?
The present data provide a clue as 
to why HIV infection, as well as ART, 
might accelerate atherosclerosis. The 
data support the shift away from a 
paradigm of delaying or stopping ART 
to reduce the risk of cardiovascular 
disease and raise the possibility that 
antiretroviral drugs without direct 
metabolic effects may actually reduce 
cardiovascular risk. The data also 
emphasize the need for clinicians to 
consider all the metabolic effects (in 
particular the ratio of total cholesterol 
to HDL) of each antiretroviral drug, 
not just total cholesterol levels, in the 
management of cardiovascular risk in 
HIV-infected adults.
The study by Mujawar et al. also has 
important implications for developing 
new approaches for suppression of HIV 
replication. Selective LXR modulators 
under active development for 
treatment of atherosclerosis may prove 
useful as ART.
The long-term effects of each 
antiretroviral drug on HDL cholesterol, 
as well as other lipid and glycemic 
parameters, need to be more 
completely analyzed in randomized 
trials, as well as in shorter healthy 
volunteer studies. It remains to be 
determined whether new antiretroviral 
drug classes, such as HIV fusion, CCR5, 
and integrase inhibitors, will be free of 
these metabolic complications.  
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